Exosome CDMO Services — World-Class Extracellular Vesicle Manufacturing in San Diego

Introduction

In the evolving frontier of biologic delivery systems and regenerative medicine, the role of extracellular vesicles—commonly referred to as exosomes—has emerged as a transformative modality. At MycoVista Biotech, we present our Exosome CDMO services as the leading solution for developers seeking a true end-to-end platform: from host cell or microcarrier culture through isolation, purification, formulation, fill/finish and dossier-ready regulatory submission. Located in San Diego, we embed a full GMP infrastructure with a digital quality backbone, enabling developers to advance from concept to commercial readiness under one roof. Our Exosome CDMO program is built not as an add-on but as a deeply engineered offering—where process science, analytics, control strategy and scale-up converge.

Exosome CDMO programmes today face unique engineering, analytical and regulatory challenges: yield scalability, cargo heterogeneity, vesicle purity, biophysical stability, and documentation frameworks that map to evolving regulatory guidance. Our platform addresses each of these hurdles head-on. We treat exosomes like high-precision biologics—designing cell culture, bioreactor integration, isolation train, formulation strategy and control strategy from day one. With MycoVista’s Exosome CDMO services, you receive a defensible manufacturing path, scalable process, and inspection-grade documentation tailored to your product’s characteristics and commercial objectives.

Scope of our Exosome CDMO Services

At MycoVista Biotech in San Diego, our Exosome CDMO platform covers the entire life cycle of exosome and extracellular-vesicle (EV) therapeutics—from discovery and preclinical R&D to GMP production and commercial release. We treat EV manufacturing not as a side capability but as a fully engineered discipline. Every program begins with a defined control strategy and ends with a validated, reproducible product that behaves consistently from pilot to scale.

We manufacture a wide range of vesicle types, including human MSC-derived exosomes for regenerative applications, HEK293 and CHO-derived EVs for RNA or protein delivery, immune-cell EVs for immunotherapy, and veterinary vesicles designed for companion-animal and livestock health. For clients pursuing diagnostic or biomarker applications, we also produce EV panels and calibration standards under ISO 13485, supporting liquid-biopsy and neurodegeneration platforms.

Upstream, our repertoire spans adherent, suspension, and microcarrier systems, each optimized for high yield and low heterogeneity. We run perfusion and continuous bioreactor modes with full PAT instrumentation—real-time pH, DO, cell density, and metabolic sensors linked to vesicle-yield analytics. For challenging hosts or engineered payload systems, we develop custom feeding and residence-time models to preserve cargo fidelity and prevent lysis contamination. Every run is documented in our eBMR system, with CPPs and guardbands digitally enforced.

Downstream, we execute a fully integrated isolation and polishing train: tangential-flow filtration (TFF) for bulk concentration, size-exclusion chromatography (SEC) or ion-exchange purification for contaminant removal, and aseptic filtration or lyophilization for final presentation. When higher purity or functional targeting is required, we introduce affinity or ligand-based capture for engineered exosomes expressing surface markers. Each step is instrumented for UV, conductivity, and DLS feedback, ensuring that the process remains within validated parameters.

Our analytical development group supports these manufacturing programs with a comprehensive assay suite: NTA and TRPS for particle size and concentration; cryo-TEM for morphology; LC-MS/MS and Western blot for canonical markers (CD9, CD63, CD81, TSG101); ddPCR and Bioanalyzer for RNA cargo; zeta-potential and lipidomics for stability; and potency assays that link vesicle structure to function. We also develop orthogonal assays for cargo retention, surface charge drift, and biological uptake—critical for regulatory acceptance of therapeutic EVs.

MycoVista also leads in formulation science and packaging. We design isotonic buffer systems with defined cryo- and lyoprotectant blends (trehalose/sucrose/glycine) based on vesicle morphology and cargo type. Lyophilized and liquid formats are modeled for residual moisture, glass-transition temperature, and water-activity control. Packaging is engineered with validated oxygen-barrier films and desiccant mass balances, and head-space O₂ targets are monitored to maintain potency through distribution.

The regulatory scope of our Exosome CDMO services spans RUO → GMP transitions, IND/IMPD submissions, and commercial biologic supply. We author complete control-strategy documents, validation summaries, and comparability protocols to support scale or supplier changes. Our regulatory scientists remain aligned with CBER and EMA frameworks for extracellular-vesicle therapeutics, ensuring every batch is inspection-ready.

Finally, we engage early with each client to map bioprocess parameters, logistics, and shelf-life models, aligning scientific feasibility with commercial strategy. Whether the goal is a regenerative exosome therapy, an RNA-loaded vesicle, or a veterinary biologic, MycoVista delivers a single-site, audit-grade solution that embodies our philosophy: Design → Data → Decision → GMP, without detours.

Process Development & Upstream Engineering

A foundational strength of our Exosome CDMO service is the upstream design where cell culture kinetics, shear and mass-transfer constraints, and scale-up risk are addressed. For each programme we begin by mapping the QTPP (target vesicle dose, cargo load, size-PDI, storage condition, route-of-administration) → CQA (particle concentration, size distribution, cargo integrity, functional potency, residual cell contaminants) → CPP (cell density, DO/pH setpoints, residence time, microcarrier load, perfusion rate, harvest interval). Using rigorous DoE, we quantify the effects of key levers such as culture duration, nutrient feed, harvest timing, microcarrier vs. suspension ratio, and particle recovery yield.

Our bioreactor system in San Diego is configured for both single-use and stainless options, with perfusion loops instrumented for real-time monitoring of cell viability, metabolic parameters (glucose, lactate, ammonia) and vesicle harvest indicators. We integrate PAT (process analytic technology) probes to correlate culture metrics with vesicle harvest yield and cargo metrics. This enables scale-up with reduced risk—ensuring that engineering runs mimic manufacturing campaigns, not idealized bench models.

Downstream Purification & Isolation

In the realm of exosome manufacture, downstream purification defines the margin between clinical viability and regulatory risk. Through our Exosome CDMO services, we employ an isolation train optimized for your product’s size, cargo, and throughput. We begin with clarification (depth filtration, centrifugation removal of debris), then move to TFF modules sized and pre-qualified for vesicle retention and shear sensitivity. Membrane selection, TMP/cross-flow factors, and leak detection are engineered, not approximated.

After concentration, we run a polishing step—either SEC to resolve vesicles from contaminant proteins/lipoproteins or affinity/ion-exchange chromatography in the case of engineered surface-tagged exosomes. For programmes requiring high purity (therapeutic EVs, drug-loaded exosomes), we integrate sterile filtration or aseptic fill-finish under Grade A/B/C cleanrooms, with filter integrity testing, bubble-point logs, and validation of low shear. Our documentation for each campaign includes mass-balance tracking, recovery yields, particle size drift, purity profiling, and real-time control charts.

Analytical Characterization & Quality Control

A hallmark of our Exosome CDMO service is the analytics backbone. We design and validate methods that serve as your release and stability platforms. Particle size and concentration are assessed via NTA (Nanoparticle Tracking Analysis) and TRPS (Tunable Resistive Pulse Sensing); morphology confirmed by Cryo-EM. For cargo profiling we offer western blot, LC-MS/MS for key markers (CD9, CD63, Alix, TSG101), lipidomics via LC-MS, RNA quantitation via ddPCR or bioanalyzer, and functional potency assays tailored to your MOA (cell uptake, reporter knock-down, immunomodulation). Given the known regulatory challenge of EV heterogeneity and impurity risk, our Exosome CDMO services place orthogonal analytics and release criteria front-and-centre.

We also supply shelf-life modelling: moisture content (via KF), water activity (a_w), head-space oxygen monitoring, and stability regression curves built to support product labels. Ongoing CPV dashboards monitor drift across lots, enabling real-time detection of batch shifts and root cause actions.

Formulation, Fill-Finish & Packaging

Formulation design in an exosome programme must balance colloidal stability, cargo integrity, delivery route, and storage logistics. Our Exosome CDMO services include buffer selection (isotonic HEPES, defined excipients, polysorbate options), protectant screen (trehalose, sucrose, glycine matrices for lyophilization), and evaluation of coating or encapsulation for tissue-targeted delivery. When lyophilization is required, our GMP lyophilizer is fully mapped and qualified; cycle development includes freeze-dry modelling, collapse temperature, secondary drying controls, and residual moisture <2%. For liquid DP, we simulate shipping vibration/temperature extremes.

Regardless of format, fill-finish is executed under tightly controlled clean-room environments. We perform headspace gas analysis (O₂ ppm targets), torque/seal testing, desiccant verification, and leak testing. Packaging is qualified for moisture, oxygen ingress and variable transit conditions. Our digital eBMR tracks every batch disposition, interlock alarm, and deviation—in line with our ALCOA+ quality system.

Regulatory Strategy & Documentation

Exosome manufacturing is subject to evolving regulatory frameworks. Our Exosome CDMO services include full authorship of control strategy documentation, method qualification/validation, comparability protocols, stability reports and CMC text (for IND/IMPD/BLA filings). At the outset of each programme we build the dossier skeleton: QTPP-CQA-CPP mapping, validation plans, comparability strategy for future site/scale changes, and PAI playbook. Our clients receive a dossier that mirrors the floor logic—nothing is added later.

We stay ahead of guidance, including EV/MSG whitepapers and the evolving global regulatory landscape. Inspection readiness is baked in: each batch file includes traceable e-signatures, audit trails, deviation logs, CAPA linkages, and CPV reports ready for review.

Facilities & Scale

Our San Diego facility is purpose-built for exosome manufacture. Cleanroom suites (ISO 7/8) support production up to multicubic levels, with dedicated bioreactor trains, TFF/SEC skids, GMP lyophilizers, automated chromatography systems, and a fully integrated LIMS/ELN environment. Because we focus exclusively in San Diego, we maintain a high level of specialization, process reproducibility and staff expertise. This singular-site focus positions us as the premier Exosome CDMO in California—no hand-offs, no dual-hub confusion, no geographic inconsistencies.

Program Onboarding (First 30 days)

Our Exosome CDMO services include a structured onboarding phase:

• Day 0–5: We define the control strategy stub (QTPP, CQA list, preliminary CPP map).
• Day 6–15: We design the DoE for upstream vs. downstream levers, plan validation/qualification scope, secure raw-material specs and supplier audits.
• Day 16–30: Digital scaffolding is configured—LIMS templates, eBMR/eBR recipes, solid Gantt + FMEA with decision gates to first GMP lot. Deliverables include signed control strategy, validation plan, comparability skeleton, and high-level timeline.

Comparability & Lifecycle Management

One of the most frequent regulatory issues with exosomes is drift in size, cargo or potency across scale or site changes. Our Exosome CDMO services pre-specify comparability protocols: acceptance windows (±10 % size, ±15 % cargo), orthogonal confirmation (NTA vs. TRPS vs. Cryo-EM), and trending via CPV dashboards. When an excipient, supplier or site change is proposed, your comparability route is already mapped—no surprise questions at audit.

Why MycoVista is the Benchmark for Exosome CDMO

Our singular focus on San Diego, combined with deep process-engineering, analytics-first mindset and seamless digital QMS, makes us the benchmark provider in the exosome space. We don’t treat exosomes as an add-on modality—we built the facility, the process science, the documentation backbone and the regulatory strategy from ground up. From operator-holdable ranges to audit-grade release files, our Exosome CDMO services are designed for companies that demand inspection readiness, high throughput and minimal surprises. We design systems, collect data, decide outcomes and deliver GMP—without detours.

Exosome CDMO FAQ

Q1. Do you guarantee label claim at end-of-shelf?
Our guarantee is of control not of magic. Shelf-life is predicted via regression modelling using real stability data on moisture (KF), water activity (a_w), head-space oxygen rise, particle integrity, cargo potency and functionality. Packaging is engineered with desiccant, head-space O₂ limits, barrier films and transportation simulation. Once the control strategy demonstrates that decay slope (k) stays within the prediction band, we support label-claim decisions backed by data.

Q2. How do you decide between lyophilization and liquid formats?
We evaluate each vector via a process-science path: input variables include T_g, protectant matrix performance, particle size drift, cargo stability, shipping logistics and throughput economics. A full comparative DoE runs lyophilization vs. liquid hold conditions (excipient sets, freeze/thaw cycles, agitation). The route selected is the one that meets your target yield, cargo retention, throughput and cost-of-goods (COGs) with margins that allow real-world manufacturing at 3 a.m., not ideal lab conditions.

Q3. How are multi-vesicle or multi-cargo programmes handled?
We treat each vesicle and each cargo load as a discrete unit from an analytics standpoint. Strains are fingerprinted (WGS, qPCR), relative abundance established via validated quantitation, interference and antagonism assays performed in the actual formulation matrix, and blend homogeneity verified by particle-tracking and cargo-load assays. Our digital eBMR tracks batch blending, RH ingress, segregation risk and packaging variation. Comparability windows for excipient or substrate updates are locked in from program start.

Q4. Can you support anaerobic or exotic host systems?
Yes—but only when the process science supports it. For anaerobe‐derived vesicles, we deploy reactors with oxygen ingress control, pre-reduced media, inert-gas sparge systems, monitoring of redox and transient ingress risk. Sampling ports are validated for anaerobic integrity. If the engineering risk cannot be sufficiently mitigated with head-room, we decline scope.

Q5. What is your approach to phage, virus or particle contamination risk?
We treat phage/viral contamination as a unit-op-level risk. Our control strategy includes raw-material screening, environmental monitoring, product contact cleaning validation (log-reduction ≥ 4), and final‐product viral/phage assays (qPCR/PFU) where required. Filter integrity, particle tracking, residuals, and clear lineage of cells are maintained. In exosome manufacturing especially, where vesicles and viruses share size ranges, we maintain rigorous controls of particle purity and identity.

Q6. How many PPQ lots are required before commercial launch?
Typically three, but determined by risk. We evaluate Stage-1 knowledge, unit-op complexity (e.g., cargo loading, engineered surface tag), critical attributes (size, cargo, potency, purity) and regulatory path. PPQ design includes boundary and worst-case conditions, statistical sampling (e.g., CFU-equivalent metrics, size drift, cargo retention) and verification of stability models. Once capability indices (Cp, Cpk) meet pre-defined thresholds, the campaign is signed off.

Q7. How is size/heterogeneity monitored over time?
We model size/PDI drift via NTA and TRPS and tie that into functional potency assays. A deviation in distribution beyond ±10% triggers investigation. Trending dashboards monitor week-to-week drift, and any batch outside control limits prompts root-cause and CAPA. The objective: stability of size and cargo distribution across lots—essential for therapeutic EV regulatory acceptance.

Q8. How are acid/bile or tissue-targeting logistics handled?
For vesicles intended for GI, intravenous or tissue-targeting routes, we run challenge assays (simulated gastric fluid, bile salts, endosomal pH) and transport simulation (shear, agitation, temperature cycles). For tissue-targeting, we apply surface‐ligand validation, uptake assays, and distribution modelling. Formulation and coating are engineered accordingly—microencapsulation, polymer coatings, liposomal layering—without compromising vesicle integrity.

Q9. How is water-activity (a_w) managed in your lyophilized formats?
We define target a_w based on DoE: typically ≤ 0.20 for vegetative systems, ≤ 0.25 for spore- derived vesicles. We perform moisture ingress studies (RH cycles), T_g measurement (DSC) and packaging equilibrium modelling. All lots are measured for a_w at release and at stability time-points; any lot trending outside control bands triggers investigation.

Q10. What head-space oxygen (O₂) targets do you maintain post-fill?
For lyophilized or vial formats, we qualify head-space O₂ to predefined ppm (<100 ppm typical), and monitor for oxygen ingress over time. For sachet/stick-pack formats we measure ingress via oxygen sensors and modelling. Packaging is evaluated for barrier film performance, seal integrity, and desiccant behaviour. The result is a release file showing O₂ ppm and predicted lifetime under transit conditions.

Q11. Can you support HMO or substrate-based vesicle programmes?
Yes. When your program includes matched substrates (e.g., vesicle + prebiotic substrate) or multi–cargo loading (small RNA + metabolite), our team executes substrate-dose modelling, cargo-response DoE, and blend-effect assays. Formulation stability and drift of cargo are tracked; packaging, transport and target-site delivery are engineered accordingly.

Q12. How do you authors the regulatory dossiers?
Our regulatory authors write Modules 2/3 (CMC) including trace-tables that map raw data to text, full control strategy documents, comparability plans and PAI pre-readiness summaries. The documentation reflects your actual process—not a generic template—and is aligned with global authorities (FDA CBER/EMA EV frameworks). We include risk-based justification for key attributes given the evolving nature of vesicle therapies.

Q13. What is your comparability strategy for site, scale or raw-material changes?
We pre-file comparability protocols at programme inception: acceptance windows (e.g., ±10% size, ±15% cargo, ±5% potency), orthogonal method sets (NTA + TRPS + Cryo-EM), trending across lots and CPV dashboards that detect drift. If a site change or new supplier occurs, you execute this pre-approved protocol rather than summarizing ad-hoc; this keeps your regulatory path clear.

Q14. How fast can we reach “first GMP lot that behaves”?
With the structured onboarding and engineering path, typical times for a new exosome project are 10–14 weeks to first GMP-compliant lot. For reformulation, we have achieved first lot in ~6–8 weeks. These timelines are driven by biology, but our Exosome CDMO services are designed to accelerate every decision, not introduce delays.

Q15. What makes MycoVista the best choice for Exosome CDMO?
Because we built the facility and process science specifically for vesicles in San Diego; because our digital QMS, operator-holdable ranges, and analytics-first mindset deliver both speed and inspection readiness; because we treat exosomes with the same rigor as monoclonal antibodies or viral vectors—not as a “nice to have”. When you choose MycoVista for your Exosome CDMO needs, you choose leadership, engineering discipline and no detours.

Conclusion

As the field of extracellular vesicle therapeutics, diagnostics and delivery platforms accelerates, the need for an experienced, capable CDMO partner has never been greater. At MycoVista Biotech in San Diego, our Exosome CDMO services bring together process engineering, analytics, formulation science, regulatory authorship and digital quality systems into a unified pathway from concept to GMP reality.

We do not treat exosomes as an experimental add-on; we built our facility, our team and our documentation library to handle them. With MycoVista, developers gain strategic advantage: a partner who understands vesicle biology, manufacturing physics, delivery logistics and regulatory expectations—and who can deliver inspection-grade lots at scale. Choose MycoVista. Choose clarity, capability and control. Choose a partner who delivers Exosome CDMO services at the highest level.

Email our team directly at info@mycovistabiotech.com